JP2023506787A5 - - Google Patents
Info
- Publication number
- JP2023506787A5 JP2023506787A5 JP2022535631A JP2022535631A JP2023506787A5 JP 2023506787 A5 JP2023506787 A5 JP 2023506787A5 JP 2022535631 A JP2022535631 A JP 2022535631A JP 2022535631 A JP2022535631 A JP 2022535631A JP 2023506787 A5 JP2023506787 A5 JP 2023506787A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutical product
- product according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946876P | 2019-12-11 | 2019-12-11 | |
| US62/946,876 | 2019-12-11 | ||
| PCT/US2020/064662 WO2021119523A1 (en) | 2019-12-11 | 2020-12-11 | Use of atr inhibitors in combination with parp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506787A JP2023506787A (ja) | 2023-02-20 |
| JP2023506787A5 true JP2023506787A5 (https=) | 2023-12-18 |
Family
ID=76316464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535631A Pending JP2023506787A (ja) | 2019-12-11 | 2020-12-11 | Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210177856A1 (https=) |
| EP (1) | EP4072551A4 (https=) |
| JP (1) | JP2023506787A (https=) |
| KR (1) | KR20220128350A (https=) |
| CN (1) | CN115103677A (https=) |
| AU (1) | AU2020402108A1 (https=) |
| BR (1) | BR112022011426A2 (https=) |
| CA (1) | CA3164203A1 (https=) |
| CL (1) | CL2022001540A1 (https=) |
| IL (1) | IL293810A (https=) |
| MX (1) | MX2022007163A (https=) |
| WO (1) | WO2021119523A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| BR112023024942A2 (pt) * | 2021-06-16 | 2024-02-15 | Repare Therapeutics Inc | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
| CN119212710A (zh) * | 2022-04-07 | 2024-12-27 | 修复治疗公司 | 使用atr抑制剂的方法 |
| US20250352539A1 (en) * | 2022-06-15 | 2025-11-20 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2024164089A1 (en) * | 2023-02-09 | 2024-08-15 | Repare Therapeutics Inc. | Use of atr inhibitors in the treatment of cancers with high tumor mutational burden |
| CN117159725B (zh) * | 2023-04-06 | 2024-07-05 | 上海交通大学医学院附属仁济医院 | 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法 |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| EP4716756A1 (en) * | 2023-05-23 | 2026-04-01 | The Francis Crick Institute Limited | Targets for treatment of alt-positive cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2305221T3 (pl) * | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| US11660301B2 (en) * | 2017-02-24 | 2023-05-30 | Bayer Pharma Aktiengesellschaft | Combination of ATR kinase inhibitors with PARP inhibitors |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-12-11 EP EP20898316.3A patent/EP4072551A4/en not_active Withdrawn
- 2020-12-11 AU AU2020402108A patent/AU2020402108A1/en not_active Abandoned
- 2020-12-11 KR KR1020227023568A patent/KR20220128350A/ko not_active Withdrawn
- 2020-12-11 US US17/119,512 patent/US20210177856A1/en not_active Abandoned
- 2020-12-11 WO PCT/US2020/064662 patent/WO2021119523A1/en not_active Ceased
- 2020-12-11 MX MX2022007163A patent/MX2022007163A/es unknown
- 2020-12-11 CA CA3164203A patent/CA3164203A1/en active Pending
- 2020-12-11 CN CN202080096191.XA patent/CN115103677A/zh active Pending
- 2020-12-11 BR BR112022011426A patent/BR112022011426A2/pt not_active IP Right Cessation
- 2020-12-11 JP JP2022535631A patent/JP2023506787A/ja active Pending
- 2020-12-11 IL IL293810A patent/IL293810A/en unknown
-
2022
- 2022-06-09 CL CL2022001540A patent/CL2022001540A1/es unknown
-
2023
- 2023-12-12 US US18/537,061 patent/US20240350505A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506787A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2020125349A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| CN103402519B (zh) | 肿瘤治疗剂 | |
| JP2022520061A5 (https=) | ||
| JP2021534168A5 (https=) | ||
| JP2021534158A5 (https=) | ||
| JP2016505512A5 (https=) | ||
| JP2019535746A5 (https=) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2016534063A5 (https=) | ||
| JP2019529444A5 (https=) | ||
| JP2015515961A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2023531709A5 (https=) | ||
| JP2026053473A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
| JP2023553534A5 (https=) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2021534160A5 (https=) | ||
| JP2014524449A5 (https=) | ||
| JP2016502540A5 (https=) | ||
| EP4346765A2 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| JP2018528949A5 (https=) | ||
| JP2024515061A5 (https=) |